 |
|
| TRAIL, 67
| |
| | |
|
|
To order this title, and for more information, click here
Gerald Litwack, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
Description
The discovery of TRAIL (TNF Related Apoptosis Inducing Ligand), also referred to as Apo-2, is in an era of intense research because TRAIL
induces many cancer cells to undergo programmed cell death (apoptosis), while having no effect on normal cells. This important protein
deserves extensive review at a formative time in the devlopement of our knowledge concerning its mechanism of action and the ways in
which it can be used as a cancer chemotherapeutic agent. Consequently, this voume reviews the current status of research on TRAIL.
Audience
Molecular biologists, cellular biologists, & biochemists
| Bibliographic details |
Hardbound, 448 pages, publication date: MAY-2004
ISBN-13: 978-0-12-709867-8
ISBN-10: 0-12-709867-4
Imprint: ACADEMIC PRESS
|
| Price and Ordering |
Price:
GBP 111.99
EUR 131.95
USD 185
|  |
Books and book related electronic products are priced in US dollars (USD), euro (EUR), and Great Britain Pounds (GBP). USD prices apply to the Americas and Asia Pacific. EUR prices apply in Europe and the Middle East. GBP prices apply to the UK and all other countries.
|
See also information about conditions of sale & ordering procedures, and links to our regional sales offices.
|
092/900
Last update: 5 Sep 2009
|
|
| |
| | |
|
|
| |
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company